Fundraising FoxPresidio Pharmaceuticals
San Francisco, US · 2 known investors
Find your way into Presidio Pharmaceuticals
Sign up to see every warm intro you have to Presidio Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Presidio Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
PV
Pamela VigExecutive
RC
Richard ColonnoExecutive
NB
Nathaniel BrownChief Medical Officer and Sr VP, Clinical DevelopmentHe brings two decades of clinical development experience in antiviral medicines, including former leadership of hepatitis drug development at GlaxoWellcome/GSK, and has contributed to multiple antiviral product registrations across North America, Europe, and Asia.
ER
Eric RubyExecutive
Board
RW
Robert WilliamsonBoard director
HD
H. Daniel PerezBoard director
SL
Scott LessingBoard director
OH
Omar HaffarBoard director
Investors · 2
Bay City CapitalreportedSan Rafael · $5M – $10M
How we know: funding news · Not right? Tell us
New Leaf Venture PartnersreportedNew York
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$21.8M disclosed across 1 round · 2013
▶$21.8MraisedJun 2014 · 16 investors · PharmaceuticalsRule 506(b)
▶$21.8MraisedJun 2014 · 16 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Robert WilliamsonDirector
- Pamela VigExecutive Officer
- Richard ColonnoExecutive Officer
- Nathaniel BrownExecutive Officer
- Eric RubyExecutive Officer
- Scott LessingDirector
- Leping LiExecutive Officer
- H. Daniel PerezDirector
- Leo RedmondExecutive Officer, Director
- Omar HaffarDirector
- Offering amount
- $22.5M
- Amount sold
- $21.8M
- Proceeds to insiders
- $1M
- First sale
- Apr 2013
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Presidio Pharmaceuticals's investors?
- Presidio Pharmaceuticals's investors include Bay City Capital, New Leaf Venture Partners.
- How much funding has Presidio Pharmaceuticals raised?
- Presidio Pharmaceuticals has disclosed $21.8M raised across 1 round.
- Where is Presidio Pharmaceuticals headquartered?
- Presidio Pharmaceuticals is headquartered in San Francisco, US.